Table 3 IVF outcome of patients included in the review

Lass et al. [1]

a) 29 SLP (ECP)

Type: unilateral

b) 73 no surgery

(healthy subjects)

pmol/L

a) 6.087 ± 2.889

b) 6.635 ± 2735

ns

a) 12.3 ± 1.6

b) 13.1 ± 2.0

ns

- General

a) 9.9 ± 5.3

b) 9.9 ± 5.3

c) Ipsilateral ovary

3.8 ± 3.0

Controlateral ovary

6.0 ± 3.6

a, b) ns

c) .01

n.r

-

a) 2.4 ± 0.5

b) 2.0 ± 0.7

ns

n.r

-

a) 17.2 (5)

b) 13.7 (10)

ns

n.r

-

Dechaud et al. [2]

a) 30 SLP (HY)

Type: not specified

b) 30 no surgery

(TF, HY)

pmol/L

a) 2.699

b) 1.903

ns

n.r

-

a) 10.1 ± 5.0

b) 10.5 ± 6.0

ns

a) 5.2 ± 3.4

b) 4.8 ± 3.7

ns

n.r

-

- First attempts

a) 10.4 (5/48)

b) 4.6 (2/43)

- All attempts

a) 13.4 (21/156)

b) 8.6 (10/116)

ns

- Per cycle

a) 23.7 (14/59)

b) 16.3 (8/49)

- Per oocyte retrieval

a) 31.8 (14/44)

b) 23.5 (8/34)

- Per transfer

a) 36.8 (14/38)

b) 25 (8/32)

ns

a) 34.2 (13/38)

b) 18.7 (6/32)

ns

Bredkjaer et al. [3]

a) 139 SLP (HY)

Type: 128 bilateral, 11 partial

b) 139 no surgery

(TF, no HY)

n.r

-

n.r

-

a) 9.3

b) 9.1

ns

n.r

-

a) 2.1

b) 2.1

ns

a) 19

b) 21

ns

a) 40.3 (106)

b) 40.5 (120)

ns

a) 21.7 (57)

b) 21.6 (64)

ns

Strandell et al. [4]

a) 116 SLP (HY)

Type: not specified

b) 88 no surgery

(TF, HY)

n.r

-

a) 11.4 ± 2.2

b) 11.6 ± 2.9

ns

a) 10.6 ± 5.9

b) 10.6 ± 6.1

ns

a) 6.8 ± 4.8

b) 7.0 ± 4.9

ns

a) 2.0 ± 0.3

b) 2.0 ± 0.4

ns

- Per transfer cycle

a) 22.8 (47/206)

b) 18.8 (28/149)

- Ultrasound visible HY

a) 30 (21/70)

b) 16.7 (13/78)

ns

.05

a) 36.6 (41)

b) 23.9 (22)

.05

a) 28.6 (32)

b) 16.3 (15)

.05

Dar et al. [5]

a) 26 SLP (ECP)

Type: 25 unilateral, 1 bilateral

Control: same patients before surgery

n.r

-

Before surgery

a) 10.81 ± 2.45

After Surgery

a) 10.68 ± 2.57

ns

Before surgery

a) - Operated site

6.06 ± 3.85

- Non operated site

5.07 ± 3.08

After Surgery

a) - Operated site

5.31 ± 4.22

- Non operated site 4.4 ± 3.68

ns

n.r

-

Before surgery

a) 3.56 ± 0.81

After Surgery

a) 3.37 ± 0.8

ns

After Surgery

a) 23.07

-

After Surgery

a) 19.23

-

n.r

-

Strandell et al. [6]

Before surgery

a) 26 SLP (general)

b) 9 unilateral

c) 17 bilateral

After Surgery

a) 26 SLP (general)

b) 9 unilateral

c) 17 bilateral

n.r

-

Before surgery

a) 11 ± 2.4

b) 12.2 ± 2.4

c) 10.4 ± 2.3

After Surgery

a) 11.2 ± 2.3

b) 12.2 ± 2.4

c) 10.6 ± 2.1

ns

Before surgery

a) 9.4 ± 5.9

b) 9.1 ± 4.4

c) 9.5 ± 6.7

After Surgery

a) 8.7 ± 5.7

b) 7.7 ± 4.6

c) 9.2 ± 6.2

ns

Before surgery

a) 7.0 ± 5.6

b) 6.4 ± 3.9

c) 7.3 ± 6.5

After Surgery

a) 5.9 ± 4.3

b) 5.3 ± 4.3

c) 6.2 ± 4.4

ns

n.r

-

n.r

-

n.r

-

n.r

-

Strandell et al. [7]

a) 103 SLP (HY)

Type: 40 unilateral, 63 bilateral

b) 82 no surgery

(TF, HY)

n.r

-

a) 11.3 ± 2.1

b) 11.4 ± 2.6

ns

a) 10.3 ± 5.4

b) 10.6 ± 5.4

ns

a) 6.8 ± 4.1

b) 7.1 ± 4.4

ns

a) 2.0 ± 0.3

b) 2.0 ± 0.3

ns

n.r

-

ODD RATIO

- Total group 1.7

- US visible HY 2.8

- US visible HY bilateral 6.9

.05

HAZARD R (BR)

- Total group 2.1

- US visible HY 3.8

US visible HY bilateral 6.0

.05

Surrey et al. [8]

a) 32 SLP (HY)

Type: not specified

b) 15 PTO (HY)

c) 35 no surgery (TF no HY)

d) 12 PTO (prior sterilization)

pg/mL

a) 2.555 ± 219

b) 2.366 ± 282

c) 2.925 ± 259

d) 2.479 ± 281

ns

a) 9.5 ± 0.2

b) 10.1 ± 0.4

c) 9.8 ± 0.2

d) 9.3 ± 0.3

ns

a) 16.2 ± 1.2

b) 14.4 ± 1.8

c) 17.5 ± 1.8

d) 12.2 ± 1.3

ns

n.r

a) 2.79 ± 0.2

b) 3.5 ± 0.4

c) 3.2 ± 0.2

d) 3.0 ± 0.3

ns

n.r

-

a) 57.1 (16/28)

b) 46.7 (7/15)

c) 52.9 (18/34)

d) 58.3 (7/12)

ns

n.r

-

Tal et al. [12]

a) 26 SLP (ECP)

Type: unilateral

b) 52 no surgery

(healthy subjects)

pmol /L

a) 5189 ± 3310

b) 5631 ± 3512

ns

a) 11.6 ± 3.1

b) 10.8 ± 2.5

ns

a) 8.6 ± 5.3

b) 8.4 ± 4.9

ns

a) 5.5 ± 3.4

b) 4.0 ± 2.3

ns

n.r

-

n.r

-

n.r

-

n.r

-

Gelbaya et al. [10]

a) 40 SLP (HY)

Type: 16 unilateral, 24 bilateral

b) 25 PTD

Type: 9 unilateral, 16 bilateral

c) 103 no surgery

(TF, no HY)

pmol/L

a) 8558 ± 4337.98

b) 11192.7 ± 4167.3

c) 9512.78 ± 4173.9

.05

a) 10.35 ± 1.92

b) 10.28 ± 1.02

c) 10.17 ± 1.37

ns

a) 10.23 ± 6.08

b) 13.68 ± 5.17

c) 12.92 ± 8.75

.05

a vs b

a) 6.78 ± 4.58

b) 8.52 ± 4.75

c) 7.80 ± 5.48

ns

n.r

-

a) 18.2 (10/55)

b) 12.8 (5/39)

c) 11 (18/163)

ns

a) 17.5 (7/40)

b) 20 (5/25)

c) 16.5 (17/103)

ns

a) 17.5 (7/40)

b) 16.0 (4)

c) 13.6 (14)

ns

Moshin & Hotineanu [11]

a) 60 SLP (HY)

b) 78 POT (HY)

c) 66 no surgery (HY)

type: not specified

n.r

-

n.r

-

a) 10.4 ± 6.0

b) 10.2 ± 5.7

c) 9.8 ± 5.5

ns

a) 7.0 ± 4.7

b) 6.9 ± 4.6

c) 6.8 ± 4.6

ns

a) 3.4 ± 1.2

b) 3.4 ± 1.3

c) 3.5 ± 1.3

ns

n.r

-

a) 38 (23/60)

b) 40 (31/78)

c) 12 (8/66)

.05

a,b vs c

n.r

-

Kontoravdis et al. [9]

a) 50 POT (HY)

b) 50 SLP (HY)

c) 15 no surgery (HY)

type: not specified

n.r.

-

a) 12.3 ± 2.4

b) 11.9 ± 2.5

c) 13 ± 1.9

ns

a) 11.6 ± 4.9

b) 12.1 ± 5.0

c) 10.9 ± 5.1

ns

a) 8.7 ± 3.9

b) 8.53 ± 4.0

c) 7.9 ± 5.1

ns

a) 2.6 ± 0.6

b) 2.6 ± 0.6

c) 2.6 ± 0.8

ns

a) 19.5

b) 24.8

c) 5.6

.03 a vs c

.007 b vs c

a) 44.4

b) 55.3

c) 14.3

.04

a vs c

.007 b vs c

a) 37.8

b) 48.9

c) 7.1

.03

a vs c

.004 b vs c

Nakagawa et al. [17]

a) 11 PTD (HY)

b) 6 SLP (HY)

type: not specified

pg/mL

a) 1553 ± 1468

b) 1530 ± 896

ns

n.r

-

a) 5.3 ± 4.7

b) 7.5 ± 5.5

ns

n.r

-

n.r

-

n.r

-

a) 45.5

b) 50.0

ns

n.r

-

Almog et al. [19]

Before surgery

(HY, ECP)

a) 36 SLP (22 unilateral, 14 bilateral)

After Surgery

a) 36 SLP

pg/mL

Before surgery

a) 1899.9 ± 185

After Surgery

a) 1997 ± 231

ns

Before surgery

a) 10.5 ± 0.6

After Surgery

a) 10.4 ± 0.4

ns

Before surgery

a) 10.2 ± 6.6

After Surgery

a) 10.3 ± 7.4

ns

n.r

-

n.r

-

n.r

-

n.r

-

n.r

-

Orvieto et al. [18]

Before surgery (HY)

a) 15 uni/bilateral

After surgery

b) 15 uni/bilateral

pg/mL

a) 1,996 ± 885

b) 2,020 ± 981

ns

b) 10.5 ± 1.7

a) 10.8 ± 1.5

ns

a) 11.6 ± 5.9

b) 10.2 ± 6.1

ns

n.r

-

a) 2.7 ± 1.1

b) 2.3 ± 0.7

ns

a) 6.7 (1/15)

b) 40 (6/15)

.05

n.r

-

Xi et al. [20]

Before surgery (ECP)

a) 76 SLP

- 44 unilateral

- 32 bilateral

After Surgery

a) 76 SLP

- 44 unilateral

- 32 bilateral

b) 80 no surgery

(healthy subjects)

pg/mL

Before surgery

a) 2663.5 ± 1246

2446.9 ± 983.8°

2512.5 ± 1119.4

After surgery

a) 2783 ± 1281.3

2860.8 ± 1509.7

2585 ± 1216.2

b) 2934.8 ± 1234.9

ns

Before surgery

a) 10.7 ± 1.5

11.1 ± 1.5

10.7 ± 1.6

After surgery:

a) 11.1 ± 1.8

11 ± 1.3

10.8 ± 1.9

b) 11.1 ± 1.8

ns

Before surgery

a) 11.1 ± 5.4

11.3 ± 5.1

11.9 ± 6.0

After surgery

a) 11.6 ± 4.1

11.1 ± 4.3

11.9 ± 5.5

b) 11.5 ± 4.4

ns

Before surgery

a) 8.3 ± 4.4

7.5 ± 2.9

8.2 ± 4.3

After surgery

a) 8.4 ± 3.9

8.4 ± 4.0

8.4 ± 3.4

b) 8.0 ± 3.1

ns

n.r

-

n.r

-

n.r

-

n.r

-

Na et al. [21]

a) 41 SLP

b) 56 sclerotherapy

type: not specified

n.r

-

n.r

-

a) 6.2 ± 1.0

b) 12.1 ± 11

ns

n.r

-

n.r

-

n.r

-

a) 40 (17/43)

b) 38 (23/60)

ns

n.r

-

Lin et al. [24]

a) 103 SLP (HY, ECP)

b) 185 (prior sterilization, tuboplasty, PTO)

type: not specified

pg/mL

a) 2153 ± 1239

b) 2340 ± 1529

ns

a) 8.8 ± 1.4

b) 8.8 ± 1.5

ns

a) 7.4 ± 3.9

b) 7.6 ± 4.1

ns

n.r

-

a) 2.5 ± 0.8

b) 2.5 ± 0.8

ns

a) 21.4 (56/261)

b) 21.0 (98/465)

ns

a) 53.5 (55/99)

b) 43.5 (77/177)

ns

a) 30.3 (30/99)

b) 25.4 (45/77)

ns

Ni et al. [22]

a) 26 bilateral SLP

b) 34 unilateral SLP

c) 23 PTO

d) no surgery (TF, no HY)

n.r

-

a) 8.15 ± 1.29

b) 8.21 ± 1.27

c) 8.83 ± 1.37

d) 8.18 ± 1.35

ns

a) 9.15 ± 3.73

b) 11.59 ± 6.14

c) 10.70 ± 4.92

d) 10.82 ± 4.82

ns

a) 6.04 ± 2.85

b) 7.74 ± 4.23

c) 7.22 ± 3.25

d) 7.57 ± 3.74

ns

a) 1.96 ± 0.45

b) 2.03 ± 0.39

c) 2.0 ± 0.43

d) 1.96 ± 0.20

ns

a) 51 (26/51)

b) 30.4 (21/69)

c) 39.1 (18/46)

d) 28 (28/100)

-

a) 65.4 (17/26)

b) 47.1 (16/34)

c) 52.2 (12/23)

d) 49 (25/51)

ns

LBR

a) 61.5 (16/26

b) 41.2 (14/34)

c) 52.2 (12/23)

d) 45.1 (23/51)

ns

Grynnerup et al. [25]

a) 16 SLP (HY)

Type: (uni/bilateral) not specified

b) 42 no surgery (TF, with or without HY)

c) 13 no surgery (unexplained infertility, no HY)

n.r

-

n.r

-

a) 7 (3–31 range)

b) 12 (3–30)

c) 9 (9–38)

.05

a vs b

n.r

-

a) 2 (1–3)

b) 2 (1–2)

c) 2 (1–2)

ns

n.r

-

n.r

-

n.r

-

Hill et al. [27]

Surgery Group (ECP)

a) 36 unilateral SLP

- pre-surgery

- post-surgery

Medical Group (ECP)

b) 153 methotrexate

- pre-treatment

- post-treatment

n.r

-

n.r

-

a) - 13 (3–31)

- 12 (3–31)

b) - 14 (2–36)

- 14 (0–35)

ns

n.r

-

n.r

-

n.r

-

a) 14 (39)

b) 68 (44)

ns

a) 13 (33)

b) 53 (35)

ns

Pereira et al. [29]

a) 107MTX (ECP) → 88 IVF

b) 37 unilateral SLP (ECP) → 22 IVF

n.r

-

a) MTX

pre 9.55 ± 1.99

post 9.76 ± 2.33

b) SLP

pre 9.63 ± 2.21

post 9.86 ± 1.93

a) ns

b) ns

a) MTX

pre 12.4 ± 5.77

post 10.6 ± 5.51

b) SLP

pre 12.2 ± 6.43

post 10.2 ± 4.23

a) .03

b) ns

n.r

-

a) MTX

pre 2.92 ± 1.24

post 2.95 ± 1.38

b) SLP

pre 2.86 ± 1.19

post 2.81 ± 1.01

a) ns

b) ns

n.r

-

n.r

-

LBR

a) MTX

post 32.95 (29)

b) SLP

post 36.3 (8)

-

Ye et al. [28]

a) 83 unilateral SLP

b) 41 bilateral SLP

c) 74 no surgery

pg/mL

a) 38.3 ± 14.91

b) 41.41 ± 16.59

c) 36.49 ± 16.77

ns

a) 9.6 ± 1.76

b) 9.39 ± 2.12

c) 9.78 ± 1.62

ns

a) 7.83 ± 4.16

b) 6.98 ± 4.15

c) 8.42 ± 4.04

ns

a) 3.39 ± 3.03

b) 3.15 ± 2.51

c) 3.5 ± 2.6

ns

n.r

-

n.r

-

n.r

-

n.r

-

Odesjo et al. [30]

a) 118 unilateral SLP

b) 35 unilateral salpingotomy

n.r

-

n.r

-

a) 11.69 ± 5.59

b) 11.8 ± 6.1

ns

n.r

-

a) 104 (88 %)

b) 30 (85.7 %)

ns

n.r

-

a) 32 (27.1 %)

b) 8 (22.9 %)

ns

LBR

a) 21 (17.8)

b) 7 (20)

ns